Table 3. Biochemical data of the two groups in follow-up.
| months | 6 months | 12 months | ||||
|---|---|---|---|---|---|---|
| Combined therapy | Double-dose | Combined therapy | Double-dose | Combined therapy | Double-dose | |
| ALT, IU/L | 28.2±18.9 | 34.1±17.2 | 29.5±11.8 | 35.3±12.7 | 29.2±14.9 | 36.1±14.3 |
| CRE, umol/L | 78.7±22.3 | 77.4±23.1 | 77.8±25.2 | 76.9±21.2 | 76.2±16.3 | 75.2±22.5 |
| TG, mmol/L | 1.3±0.9 | 1.1±0.5 | 1.3±0.7 | 1.2±0.9 | 1.4±0.9 | 1.3±0.9 |
| HDL-C, mmol/L | 1.0±0.3 | 1.1±0.4 | 1.1±0.2 | 1.2±0.3 | 1.2±0.4 | 1.2±0.3 |
| LDL-C, mmol/L | 1.4±0.5 | 1.5±0.6 | 1.3±0.5 | 1.4±0.6 | 1.2±0.6 | 1.4±0.7 |
| CK, U/L | 78.9±36.2 | 85.6±38.9 | 83.4±42.5 | 91.2±41.2 | 82.0±36.2 | 90.3±49.2 |
| hsCRP, mg/L | 2.5±1.3 | 2.1±1.2* | 1.8±1.1 | 1.7±1.1 | 1.2±1.0 | 1.1±0.8 |
* hsCRP, compared with combined therapy group, p < 0.05.
In fact, both LDL-C and hsCRP decreased faster in double-dose atorvastatin group than combined therapy in the first three months.
Abbreviations: ALT, alanine aminotransferase; CRE, creatinine; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CK, creatine kinase; hsCRP, high sensitive C-reactive protein.